Once‐Daily Single‐Inhaler Triple versus Dual Therapy in Patients with COPD

No abstract is available for this paper.

• Publication year

  2018

• Venue

  New England Journal of Medicine

• Publication date

  2018-04-18

• Fields of study

  Medicine

• Identifiers
  DOI 10.1056/NEJMoa1713901PMID 29668352
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease 2017 Report. GOLD Executive Summary.

  2017cited by this paper
• Making Patients and Doctors Happier - The Potential of Patient-Reported Outcomes.

  2017cited by this paper
• Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease 2017 Report: GOLD Executive Summary

  2017cited by this paper
• Single inhaler extrafine triple therapy versus long-acting muscarinic antagonist therapy for chronic obstructive pulmonary disease (TRINITY): a double-blind, parallel group, randomised controlled trial.

  2017cited by this paper
• FULFIL Trial: Once‐Daily Triple Therapy for Patients with Chronic Obstructive Pulmonary Disease

  2017cited by this paper
• Single inhaler triple therapy versus inhaled corticosteroid plus long-acting β2-agonist therapy for chronic obstructive pulmonary disease (TRILOGY): a double-blind, parallel group, randomised controlled trial.

  2016cited by this paper
• Indacaterol-Glycopyrronium versus Salmeterol-Fluticasone for COPD.

  2016cited by this paper
• Fluticasone furoate and vilanterol and survival in chronic obstructive pulmonary disease with heightened cardiovascular risk (SUMMIT): a double-blind randomised controlled trial.

  2016cited by this paper
• Initiation of triple therapy maintenance treatment among patients with COPD in the US

  2016cited by this paper
• A phase III randomised controlled trial of single-dose triple therapy in COPD: the IMPACT protocol

  2016cited by this paper
• Efficacy and safety of umeclidinium added to fluticasone furoate/vilanterol in chronic obstructive pulmonary disease: Results of two randomized studies.

  2015cited by this paper
• Treatment Evolution after COPD Diagnosis in the UK Primary Care Setting

  2014cited by this paper
• Benefits of adding fluticasone propionate/salmeterol to tiotropium in moderate to severe COPD.

  2012cited by this paper
• Observational study on the impact of initiating tiotropium alone versus tiotropium with fluticasone propionate/salmeterol combination therapy on outcomes and costs in chronic obstructive pulmonary disease

  2012cited by this paper
• Comparison of tiotropium plus fluticasone propionate/salmeterol with tiotropium in COPD: a randomized controlled study.

  2012cited by this paper
• The impact of tiotropium on mortality and exacerbations when added to inhaled corticosteroids and long-acting β-agonist therapy in COPD.

  2012cited by this paper
• Efficacy and tolerability of budesonide/formoterol added to tiotropium in patients with chronic obstructive pulmonary disease.

  2009cited by this paper
• Tiotropium in Combination with Placebo, Salmeterol, or Fluticasone-Salmeterol for Treatment of Chronic Obstructive Pulmonary Disease: A Randomized Trial

  2008cited by this paper
• POCKET GUIDE TO COPD DIAGNOSIS, MANAGEMENT, AND PREVENTION A Guide for Health Care Professionals

  2007cited by this paper
• Tiotropium in Combination with Placebo, Salmeterol, or FluticasoneSalmeterol for Treatment of Chronic Obstructive Pulmonary Disease

  2007cited by this paper
• A pilot study to assess the effects of combining fluticasone propionate/salmeterol and tiotropium on the airflow obstruction of patients with severe-to-very severe COPD.

  2007cited by this paper

• Single-Inhaler Triple Therapy (SITT) for COPD: An Italian expert opinion paper on improving clinical outcomes and equity of therapeutic access.

  2026influential citation
• Development and Validation of an Electronic Health Record Algorithm to Predict the Presence of Chronic Obstructive Pulmonary Disease

  2026cites this paper
• FF/UMEC/VI and BUD/GLY/FORM in Patients with COPD Stepping Up from Dual Therapy Stratified by Exacerbations and Prior Dual Therapy: A Subgroup Analysis of a Comparative Effectiveness Study.

  2026cites this paper
• Inhalation: A Smart Strategy and Increasing Potential for Drug Delivery.

  2026cites this paper
• Economic evaluation of single-inhaler triple therapy for chronic obstructive pulmonary disease in Thailand

  2026cites this paper
• The Airway Microbiome in Chronic Obstructive Pulmonary Disease (COPD): A Guide for Clinicians.

  2026cites this paper
• A pragmatic, multicentre, placebo-controlled, 3-arm, double-blinded, randomised controlled trial, incorporating an internal pilot, to determine the role of bronchodilators in preventing exacerbations of bronchiectasis.

  2026cites this paper
• Excessive Short-acting Beta-agonists Prescriptions in COPD Treated with Triple Inhaler Therapy: A Possible Marker of Frequent Exacerbations. A Retrospective Cohort Study

  2026cites this paper
• Short-Term Effects of Dupilumab in Eosinophilic COPD

  2026cites this paper
• Prior pulmonary tuberculosis deteriorated all-cause mortality in AECOPD patients after discharge

  2026cites this paper
• Risk of Hospitalized COVID‐19 in COPD: Single‐Inhaler Triple Versus Dual Bronchodilator Therapy

  2026cites this paper
• Management of Chronic Obstructive Pulmonary Disease: An Evidence-Based Synthesis of Recent Advances (2018–2025)

  2025cites this paper
• A cross-sectional study on the impact of methylxanthines, corticosteroids, and antibiotics on COPD symptoms: Assessment using CAT, mMRC, and GOLD criteria

  2025cites this paper
• Comparable Clinical Outcomes with Tiotropium/Olodaterol or Fluticasone Furoate/Umeclidinium/Vilanterol in Patients with COPD and Blood Eosinophil Count ≤300 Cells/μL

  2025cites this paper
• Treatment Patterns and Triple Therapy Utilization in Chinese Patients with Chronic Obstructive Pulmonary Disease: An Analysis of Real-World Data from the Yinzhou Database

  2025cites this paper
• Clinically Important Improvements and Disease Stability with Fluticasone Furoate/Umeclidinium/Vilanterol Once-Daily Single-Inhaler Triple Therapy in the ELLITHE Trial: A Post Hoc Responder Analysis

  2025cites this paper
• Comparing Major COPD Triple Therapy Trials Using a Structured Multi-Criteria Decision Analysis: A Deep Dive into Patient Populations and Outcomes.

  2025cites this paper
• Sex-Specific Safety Signals of Trelegy Ellipta: A FAERS Pharmacovigilance Analysis

  2025cites this paper
• Effect of Cumulative Tobacco Exposure on Blood Eosinophil Level in Chronic Obstructive Pulmonary Disease

  2025cites this paper
• Effect of Preoperative Single-Inhaler Triple Therapy on Pulmonary Function in Lung Cancer Patients with Chronic Obstructive Pulmonary Disease and FEV1 < 1.5 L

  2025cites this paper
• Healthcare resource utilisation in patients with exacerbations of COPD and associated cardiovascular events: the EXACOS-CV study

  2025cites this paper
• Characteristics and real-world health clinical outcomes of uncontrolled COPD patients: population-based study in France

  2025cites this paper
• Comparison of clinical outcome of COPD with asthma-like feature with different inhalation therapies: a real-world study in the prospective RealDTC cohort

  2025cites this paper
• Predictors of Clinical Stability and Mortality in COPD: A Longitudinal Study

  2025cites this paper
• Evaluation of the Effects of Switching COPD Patients From LAMA/LABA Therapy to ICS/LAMA/LABA Therapy Using the Impulse Oscillation System (IOS) Capable of Separating Inspiratory and Expiratory Measurements

  2025cites this paper
• Extracellular vesicles from bronchoalveolar lavage fluid provide insights into the inhaled corticosteroids treatment response in COPD

  2025cites this paper
• Economic Analysis of New Single-Inhaler Triple Therapies in Patients with COPD in the UK

  2025cites this paper
• Role of Inhaled Therapies in COPD Progression and Exacerbation Prevention: A Critical Review

  2025cites this paper
• Randomized Sham-controlled Trial of Targeted Lung Denervation in Patients with Chronic Obstructive Pulmonary Disease (AIRFLOW-3)

  2025cites this paper
• Treatment of chronic obstructive pulmonary disease: current pipeline and new opportunities

  2025cites this paper
• Rationale and Design of the Alpha-1 Biomarkers Consortium Study.

  2025cites this paper
• Prevalence of microspirometry-detected chronic obstructive pulmonary disease in two European cohorts of patients hospitalised for acute myocardial infarction: a cross-sectional study

  2025cites this paper
• Burden of Exacerbations in Patients Newly Initiating an Inhaled Regimen for COPD: A Claims Analysis

  2025influential citation
• The Case for Case Finding Is Getting Stronger

  2025cites this paper
• Association of echocardiographic pulmonary hypertension with all-cause mortality in hospitalized AECOPD patients

  2025cites this paper
• Acupuncture improves the symptoms, gut microbiota, metabolomics, and inflammation of patients with chronic obstructive pulmonary disease: a multicenter, randomized, sham-controlled trial protocol

  2025cites this paper
• Differences in Blood Eosinophil Level During Stable Disease and During Exacerbation of COPD and Exacerbation Risks

  2025cites this paper
• Reply to Hsiao and Chen: Refining the Concept of Disease Stability in Chronic Obstructive Pulmonary Disease: Bridging Complexity and Clinical Practice

  2025cites this paper
• Effects of Triple Therapy on the Clinical Course of Non-Eosinophilic COPD Groups B

  2025cites this paper
• Characteristics of Patients Initiated on Budesonide/Glycopyrronium Bromide/Formoterol Fumarate Single Inhaler Triple Therapy for the Treatment of Chronic Obstructive Pulmonary Disease: A Population-Based Observational Study

  2025influential citation
• Advancing Obstructive Airway Disease Treatment: Dual PDE3/4 Inhibition as a Therapeutic Strategy

  2025cites this paper
• Step up to triple therapy versus switch to dual bronchodilator therapy in patients with COPD on an inhaled corticosteroid/long-acting β2-agonist: post-hoc analyses of KRONOS

  2025cites this paper
• From acute phase to rehabilitation: bridging the gap and improving the pathway for Chronic Obstructive Pulmonary Diseases patients (Summary of a Pulmonologists’ Audit - September–December 2024)

  2025cites this paper
• Single-Inhaler Triple Therapy in Primary Care Across Europe: Expert Panel Consensus on the Consequences of Payer-Driven Access Rules and Call to Action

  2025cites this paper
• Managing Small Airways Dysfunction in COPD Patients in Real Life Under Fixed Triple Combination of Beclomethasone/Formoterol/Glycopyrronium: The MASCOT Real World Evidence Study

  2025cites this paper
• Eosinophils in chronic obstructive pulmonary disease

  2025cites this paper
• Pharmacologic Treatment of COPD: Disparities Between Evidence and Recommendations in GOLD 2023/4

  2025cites this paper
• The clinical effectiveness of sodium-glucose co-transporter-2 inhibitors on prognosis of patients with chronic obstructive pulmonary disease and diabetes

  2025cites this paper
• Comparative Effectiveness of FF/UMEC/VI and BUD/GLY/FORM in Patients with COPD Stepping Up From Dual Therapy

  2025cites this paper
• Real-world effectiveness study of guideline-directed COPD STANDARDized management in patients with chronic obstructive pulmonary disease: a cluster randomised trial design

  2025influential citation
• Real-world effectiveness of single-inhaler fluticasone furoate/umeclidinium bromide/vilanterol in Chinese patients with symptomatic chronic obstructive pulmonary disease (COPD): a post-marketing, prospective, multicenter, observational study

  2025cites this paper
• Effect of triple therapy on mortality and cardiovascular risk in patients with moderate to severe COPD: a meta-analysis of randomized controlled trials

  2025cites this paper
• Effect of budesonide/glycopyrronium/formoterol fumarate dihydrate on cardiopulmonary outcomes in COPD: rationale and design of the THARROS trial

  2025cites this paper
• The global burden of COPD: epidemiology and effect of prevention strategies.

  2025cites this paper
• Diagnosing Type 2 Inflammation in COPD: Comparison of Blood and Sputum Eosinophil Assessment in the University of California Los Angeles COPD Phenotyping Study.

  2025cites this paper
• Management of COPD With Cardiovascular Risk in Asia: A Review by the Asian Pacific Society of Respirology COPD Assembly

  2025cites this paper
• Use of a Personalised Early Warning Decision Support System for Acute Exacerbations of Chronic Obstructive Pulmonary Disease: Results of the “Predict & Prevent” Phase III Trial

  2025cites this paper
• Safety and Efficacy of Budesonide/ Glycopyrrolate/Formoterol Fumarate (BGF) compared to Glycopyrrolate/ Formoterol Fumarate (GFF) for the Treatment of COPD: A Systematic Review & Meta Analysis.

  2025cites this paper
• Association between eosinophil count and prognosis in chronic obstructive pulmonary disease patients

  2025cites this paper
• Assessing inpatient formulary-driven inhaler use in presumed Group B chronic obstructive pulmonary disease.

  2025cites this paper
• Rectifying COPD management: a critical analysis of the Global Initiative for Chronic Obstructive Lung Disease strategy

  2025cites this paper
• Real-World Outcomes in Patients with COPD Initiating Budesonide/Glycopyrronium/Formoterol Fumarate Dehydrate in Spain: ORESTES Study

  2025cites this paper
• Comparative Study of Dual Therapy vs Triple Therapy in Severe COPD Management

  2025cites this paper
• Should all patients with COPD be treated with inhaled triple therapy?

  2025cites this paper
• Glucose-Lowering Medications and Risk of Chronic Obstructive Pulmonary Disease Exacerbations in Patients With Type 2 Diabetes.

  2025cites this paper
• What’s new in the 2025 GOLD report

  2025cites this paper
• Pharmacologic Therapies for Preventing Chronic Obstructive Pulmonary Disease Exacerbations: A Comprehensive Review

  2025cites this paper
• Barriers and enablers to medicine-taking behaviours in chronic obstructive pulmonary disease: a qualitative interview study

  2025cites this paper
• Adherence to Pharmacological Management Guidelines for Stable Chronic Obstructive Lung Disease

  2025influential citation
• Inhaled corticosteroids in chronic obstructive pulmonary disease: a systematic review and meta-analysis on mortality protection - making a long story short

  2025influential citation
• All-Cause and Cardiovascular Mortality With Single Inhaler Triple Therapy Versus Double Therapies for COPD: A Systematic Review and Metanalysis.

  2025cites this paper
• A Delphi Consensus Project to Capture Greek Experts’ Opinion on the Position of Triple Therapies in COPD: Why, When and to Whom

  2025cites this paper
• Safety and outcomes of bronchoscopic lung volume reduction with endobronchial valves under moderate sedation

  2025cites this paper
• Real-World Outcomes of Single-Inhaler Triple Therapy Prescribed by General Practitioners in Managing Chronic Obstructive Pulmonary Disease: A Systematic Literature Review

  2025cites this paper
• Predictors of treatment REsponse to inhaled corticosteroids (ICS) in Chronic Obstructive pulmonary disease: randomised controlled trials individual participant Data re-Evaluation–protocol of the ICS-RECODE individual participant data meta-analysis

  2025cites this paper
• Access to single-inhaler triple medicines for chronic obstructive pulmonary disease in China: a national survey on accessibility and utilisation

  2025influential citation
• POTENTIAL DRUG DELIVERY SYSTEMS AND DEVICE COMBINATION FOR THE MANAGEMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE

  2025cites this paper
• Effect of triple inhaled therapy on cardiovascular and all-cause mortality compared with dual inhaled therapy in COPD: A systematic review and meta-analysis.

  2025cites this paper
• Impact of inhaled corticosteroids on metabolic dysfunction-associated steatotic liver disease risk in COPD patients.

  2025cites this paper
• Association between Income, Neighborhood Vulnerability, and 5-Year Survival after COPD Hospitalization in Medicare Beneficiaries.

  2025cites this paper
• Recommendations for Improving Discharge-Related Care Following a COPD Exacerbation: An Expert Panel Consensus with Emphasis on Low- and Middle-Income Countries

  2025cites this paper
• COPD Exacerbations and Airflow Obstruction Severity Pre- and Post-Pneumococcal Vaccination: A post hoc Analysis of the RETRIEVE Real-World Study

  2025cites this paper
• Optimizing COPD Treatment: The Role of Inhaled Corticosteroids and Bronchodilators

  2025cites this paper
• Evaluating Adherence to the 2023 Canadian Thoracic Society Chronic Obstructive Pulmonary Disease Pharmacotherapy Guidelines: A Hospital-Based Study

  2025cites this paper
• Ensifentrine: a novel approach to redefining COPD management and implications for additional respiratory diseases

  2025cites this paper
• Increasing Quality and Quantity of Life in Individuals with Chronic Obstructive Pulmonary Disease: A Narrative Review with an Emphasis on Pulmonary Rehabilitation

  2025cites this paper
• AN OVERVIEW OF COPD: ITS ADVANCED THERAPEUTIC MANAGEMENT AND CHALLENGES FOR DRUG RELEASE AT THE TARGETED SITE

  2025cites this paper
• Real-life impact of anti-IL5 therapy on exacerbation types in patients with obstructive lung disease

  2025influential citation
• Patient response and remission in respiratory disease: Special focus on severe asthma and chronic obstructive pulmonary disease

  2025cites this paper
• Quinine Use and the Risk of Exacerbations of Chronic Obstructive Pulmonary Disease: A Nationwide Retrospective Registry Study

  2025cites this paper
• Clinical characteristic of patients with COPD-A

  2025cites this paper
• HOW I DO IT Selecting An Inhaled Delivery System in COPD.

  2025cites this paper
• Dose of Inhaled Corticosteroid in Chronic Obstructive Pulmonary Disease and Risks of Osteoporosis or Fracture—A Systematic Review and Meta‐Analysis

  2025cites this paper
• Smoking gun: when COPD therapies fail current smokers

  2025cites this paper
• Effect of Added Inhaled Corticosteroids to Systemic Steroids on COPD Exacerbation Outcomes

  2025cites this paper
• Real-world effectiveness of budesonide/glycopyrronium/formoterol fumarate metered dose inhaler on symptoms and quality of life in patients with COPD: EBISU study.

  2025cites this paper
• Cost-Effectiveness of Single-Inhaler Versus Multiple-Inhaler Triple Therapy in COPD: A German Healthcare Perspective

  2025cites this paper
• Cardiopulmonary Risk in Chronic Obstructive Pulmonary Disease　- A Perspective for Reducing Mortality.

  2025cites this paper
• Comparison of the Risk of Pneumonia Between Fluticasone Furoate/Umeclidinium/Vilanterol and Multiple-Inhaler Triple Therapy in Patients with COPD Using Health Insurance Claims Data: Final Analysis of Post-Marketing Database Surveillance in Japan

  2025influential citation
• Current Smoker: A Clinical Chronic Obstructive Pulmonary Disease Phenotype Affecting Disease Progression and Response to Therapy

  2025cites this paper